FDA Approves Binimetinib/Encorafenib for BRAF+ Melanoma
Pharma & biotech2018-06-27
12 Views
The FDA has approved the combination of the BRAF inhibitor encorafenib (Braftovi) and the MEK inhibitor binimetinib (Mektovi) for the treatment of patients with BRAF-mutant unresectable or metastatic melanoma, as detected by an FDA-approved test.
Source: OncLive
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
Sponsored Post
Pass Microsoft MTA Certification Exams to Gain Entry into IT Industry
